FLINT, Mich., Sept. 22, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is aware of unusual market activity in its stock today, potentially in respect to a deal in which Diplomat was incorrectly referenced. Diplomat is aware of a recent development regarding Depomed Inc.and Horizon Pharma PLC, in which it is not involved. Diplomat heard from an investor today that the Diplomat name was incorrectly referenced instead of Depomed, in a discussion between that investor and a bank earlier today. We reference such statement only to explain the potential market confusion and we are not commenting on the validity of the statement in any respect. Diplomat has noted that in terms of both shares traded (relative to usual trading volumes) and stock price decline thus far today, its stock is unusually correlated to Depomed Inc. and Horizon Pharma PLC.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
CONTACT: INVESTOR CONTACT Bob East, Westwicke Partners 443.213.0500 | firstname.lastname@example.org
MEDIA CONTACT Jenny Cretu, Diplomat 810.768.9370 | email@example.com
SOURCE Diplomat Pharmacy, Inc.